Through years 1-5, ARR remained low in MS patients receiving continuous ocrelizumab (ranging from 0.07 in year 5 to 0.14 over year 1), whereas in previously IFN-treated patients it was significantly reduced by 52% after switching to ocrelizumab (ARR 0.10 in year 3, and 0.07 in year 5). The gene discussed is IFNA1; the disease is myeloid sarcoma.